Gilead Sciences (GILD) Tops Q4 EPS by 4c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
February 4, 2021 4:01 PM EST
  Fourth Quarter 2020 Year-Over-Year:
- Product Sales increased 26% to $7.3 billion, primarily due to Veklury® (remdesivir) -
- Diluted EPS of $1.23; Non-GAAP Diluted EPS of $2.19 -
Full Year 2020 Year-Over-Year:
- Product Sales increased 10% to $24.4 billion, primarily due to Veklury -
- Diluted EPS of $0.10; Non-GAAP Diluted EPS of $7.09 -
- Returned $5.0 billion of cash to shareholders through dividends and share repurchases -
Full Year 2021 Guidance:
- Product Sales including Veklury of $23.7... More
